0VQ.F PURETECH HEALTH PLC LS 1
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0VQ.F undervalued?
Graham numberThe Graham number of PURETECH HEALTH PLC LS 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PURETECH HEALTH PLC LS 1 fundamental analysis
No fundamental analysis for PURETECH HEALTH PLC LS 1 yet.
PURETECH HEALTH PLC LS 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PURETECH HEALTH PLC LS 1
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnano…
Full company profileFinancial statements of PURETECH HEALTH PLC LS 1 are not available yet.
PURETECH HEALTH PLC LS 1 dividends
PURETECH HEALTH PLC LS 1 has not paid dividends in the last 4 fiscal years.
Who owns PURETECH HEALTH PLC LS 1
- Insiders 10.00%
- Institutions 56.92%
- Public & others 33.08%
- Free float 162M
PURETECH HEALTH PLC LS 1 company profile
- Company name
- PURETECH HEALTH PLC LS 1
- Ticker
- 0VQ.F
- ISIN
- GB00BY2Z0H74
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 90
- Fiscal year end
- December
- Address
- 6 Tide Street, Boston, MA, United States, 02210
- Phone
- 617 482 2333
- Website
- puretechhealth.com
About PURETECH HEALTH PLC LS 1
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.
PURETECH HEALTH PLC LS 1 management
10- Mr. Robert Lyne J.D., L.L.B.CEO & Director · born 1983
- Dr. Robert S. Langer Jr., Ph.D., ScDCo-Founder & Non-Executive Director · born 1949
- Dr. Eric Elenko Ph.D.Co-founder · born 1973
- Dr. David R. Elmaleh Ph.D.Co-Founder & Senior Advisor · born 1948
- Ms. Lauren A. White M.B.A.Chief Financial Officer · born 1979
- Mr. Michael Inbar CPA, M.B.A.Chief Accounting Officer
- Ms. Allison Mead TalbotSenior VP of Communications & Head of Investor Relations
- Ms. Aleksandra Filipovic M.D., Ph.D.Head of Oncology
- Ms. Joy Bauer M.S., RDNChief Nutrition Officer
- Dr. Camilla S. Graham M.D., M.P.H.Senior Vice President of Medical Affairs